Back to News
Market Impact: 0.22
MiniMed Group Consensus Price Target Increased by 20.43% to $26.24
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
MiniMed Group's aggregate one-year analyst price target was raised 20.43% to $26.24 per share as of September 15, 2026, from $21.79 on August 25. The upward revision signals improved analyst expectations for the medical-technology company, though the article provides no underlying earnings, operational, or guidance catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.32
Ticker Sentiment
MMED0.42
More News
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Inside South Korea’s university programs offering a direct route to Samsung and SK Hynix
- DST Global Advisors sells $6.86m in Chime Financial stock
- Why Radiant Logistics Stock Topped the Market on Tuesday
- DST Global Advisors sells $6.86 million in Chime Financial stock
- Micron’s 12.4x forward P/E and the case for an AI memory re-rating